Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a rando-mised, double-blind, placebo-controlled, phase 3 trial.

Gnant, M; Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

https://pubmed.ncbi.nlm.nih.gov/30795951/